<SEC-DOCUMENT>0001193125-26-117738.txt : 20260320
<SEC-HEADER>0001193125-26-117738.hdr.sgml : 20260320
<ACCEPTANCE-DATETIME>20260320163027
ACCESSION NUMBER:		0001193125-26-117738
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20260320
DATE AS OF CHANGE:		20260320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Coya Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001835022
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-294315
		FILM NUMBER:		26778613

	BUSINESS ADDRESS:	
		STREET 1:		12645 MEMORIAL DR., SUITE F1 #305
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77024
		BUSINESS PHONE:		650.739.3939

	MAIL ADDRESS:	
		STREET 1:		12645 MEMORIAL DR., SUITE F1 #305
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77024
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d206837d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) <BR> Registration No. 333-294315 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g206837g12p03.jpg" ALT="LOGO" STYLE="width:2.13986in;height:0.893806in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Coya Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>2,522,727 Shares of Common Stock </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the resale of up to 2,522,727 shares of Coya Therapeutics, Inc. (the &#8220;Company,&#8221; &#8220;we,&#8221;
&#8220;our,&#8221; or &#8220;us&#8221;) common stock, par value $0.0001 per share (&#8220;common stock&#8221;), by the selling stockholders listed in this prospectus or their permitted transferees. The shares of common stock registered for resale
pursuant to this prospectus include 2,522,727 shares of common stock (the &#8220;Shares&#8221;) issued in a private placement (the &#8220;Private Placement&#8221;) pursuant to a Securities Purchase Agreement entered into on January&nbsp;29, 2026
with certain accredited investors party thereto (the &#8220;Securities Purchase Agreement&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not receive any of the
proceeds from the sale of the Shares by the selling stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders, or their permitted transferees or other <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest,</FONT></FONT> may sell the Shares of common stock described in this prospectus in a number of different ways and at varying prices. See &#8220;<I>Plan of
Distribution</I>&#8221; on page 14 of this prospectus for more information on how the selling stockholders may sell the Shares of common stock pursuant to this prospectus. Certain of the selling stockholders may be &#8220;underwriters&#8221; within
the meaning of Section&nbsp;2(a)(11) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay the
expenses incurred in registering the resale of the Shares, including legal and accounting fees. See &#8220;<I>Plan of Distribution</I>&#8221; on page 14 of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should read the entire
prospectus and any amendments or supplements carefully before you make your investment decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth
company&#8221; as defined in Section&nbsp;2(a) of the Securities Act, and we have elected to comply with certain reduced public company reporting requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;COYA.&#8221; The last reported sale price for our common stock
on March&nbsp;19, 2026 as quoted on the Nasdaq Capital Market was $4.27 per share. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B></B><B><I>Investing in our securities involves a high degree of risk. See &#8220;<A HREF="#tx206837_5">Risk Factors</A>&#8221; beginning on
page 8 of this prospectus and the documents incorporated by reference into this prospectus for a discussion of the risks that you should consider in connection with an investment in our securities.</I></B><B></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is March 20, 2026. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx206837_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx206837_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx206837_3">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx206837_4">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx206837_5">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx206837_6">DESCRIPTION OF THE TRANSACTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx206837_7">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx206837_8">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx206837_9">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx206837_10">DESCRIPTION OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx206837_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx206837_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx206837_13">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx206837_14">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx206837_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the selling stockholders have authorized anyone to provide you with any information other than that contained in, or
incorporated by reference into, this prospectus. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of our common
stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should not assume that the information contained in or incorporated by reference in this prospectus is accurate as of any date other than their
respective dates. Our business, financial condition, results of operations and prospects may have changed since those dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus
supplement may add to, update or change the information contained in this prospectus. You should read both this prospectus and any applicable prospectus supplement together with additional information described below under the heading
&#8220;<I>Where You Can Find More Information</I>.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Throughout this prospectus, when we refer to the selling stockholders, we are
referring to the selling stockholders identified in this prospectus and, as applicable, their permitted transferees or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> that may be
identified in a supplement to this prospectus or, if required, a post-effective amendment to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the
actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as
exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading &#8220;<I>Where You Can Find More Information</I>.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this prospectus, unless otherwise stated or unless the context otherwise requires, references to &#8220;Coya,&#8221; &#8220;Company,&#8221;
&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or similar references mean Coya Therapeutics, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx206837_2"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and any documents we incorporate by reference, contain certain forward-looking statements that involve substantial risks and
uncertainties. All statements contained in this prospectus and any documents we incorporate by reference, other than statements of historical facts, are forward-looking statements including statements regarding our strategy, future operations,
future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221;
&#8220;may,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue&#8221; and
similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop, obtain regulatory approval for and commercialize our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of future investigational new drug (&#8220;IND&#8221;) submissions, initiation of preclinical studies
and clinical trials, and timing of expected clinical results for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our success in early preclinical studies, which may not be indicative of results obtained in later studies or
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outbreak of public health emergencies, epidemics, pandemics, which could adversely impact our business,
including our preclinical studies and any future clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify patients with the diseases treated by our product candidates, and to enroll patients in
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of our efforts to expand our pipeline of product candidates and develop marketable products through
the use of our potential therapeutic modalities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding collaborations and other agreements with third parties and their potential benefits;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain, maintain and protect our intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance upon intellectual property licensed from third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impacts of increased trade tariffs, import quotas or other trade restrictions or measures taken by the United
States and other countries, including the recent and potential changes in U.S. trade policies that may be made by the Trump presidential administration; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify, recruit and retain key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments or projections relating to our competitors or our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our
Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties, including those listed in the &#8220;Risk Factors&#8221; section of this
prospectus and the documents incorporated by reference herein. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements are only predictions and we may not actually achieve the
plans, intentions or expectations disclosed in our forward-looking statements, so you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations
disclosed in the forward-looking statements we make. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and
operating results. We have included important factors in the cautionary statements included in this prospectus, as well as certain information incorporated by reference into this prospectus, that could cause actual future results or events to differ
materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Discussions containing these forward-looking statements may be found, among other places, in the sections titled &#8220;Business,&#8221;
&#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; incorporated by reference from our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the
fiscal year ended December&nbsp;31, 2025 filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March&nbsp;16, 2026, as well as any amendments thereto filed with the SEC. Additional factors are discussed under the caption
&#8220;<I>Risk Factors</I>&#8221; in this prospectus and any free writing prospectus and under similar headings in the other documents that are incorporated by reference into this prospectus. New risks and uncertainties arise from time to time, and
it is impossible for us to predict these events or how they may affect us. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may
be required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus with the understanding that our actual future results may be materially different
from what we expect. We do not assume any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx206837_3"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information that you
should consider before deciding to invest in our securities. You should read this entire prospectus carefully, including the &#8220;Risk Factors&#8221; section in this prospectus and under similar captions in the documents incorporated by reference
into this prospectus. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells
(&#8220;Tregs&#8221;). Tregs are a subpopulation of <FONT STYLE="white-space:nowrap">T-lymphocytes</FONT> consisting of CD4+CD25high hFOXP3+ cells that suppress inflammatory responses. Tregs were first discovered in 1995 by Dr.&nbsp;Shimon
Sakaguchi. On October&nbsp;6, 2025, Dr.&nbsp;Sakaguchi, along with two others, was awarded the Nobel Prize in Physiology or Medicine. Since Tregs were discovered, multiple lines of research have contributed to elucidate Treg biology and its role in
health and disease. Tregs and their transcription factors have been shown to be essential to maintaining cellular homeostasis by regulating autoimmune and inflammatory responses and maintaining self-tolerance in mammals. Dysfunctional Tregs underlie
numerous disease states, and this cellular dysfunction is driven by the chronic inflammatory environment and high levels of oxidative stress commonly observed in certain diseases. Further, the degree of Treg dysfunction is correlated with the
severity and progression of serious and life-threatening conditions. These and other recent advances in the understanding of Treg biology, have made this subset of <FONT STYLE="white-space:nowrap">T-lymphocytes</FONT> an important potential
therapeutic target, which we believe may provide new treatments for serious diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our core focus is developing therapies to target
Treg dysfunction. Treg disfunction has been identified as an important pathophysiological component of neurodegenerative, autoimmune, and metabolic diseases, all areas where we believe new and effective therapies are urgently needed. We believe we
have expertise in three distinct potential therapeutic modalities: Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Our expertise includes both <I>ex vivo </I>and <I>in vivo </I>approaches intended to restore the
suppressive and immunomodulatory functions of Tregs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead asset, COYA 302, is a Treg-enhancing biologic, which was developed from key
learnings established in our early work and discoveries of our autologous Treg cell therapy asset. Our autologous Treg cell therapy program has completed a Phase 1 and Phase 2a studies in amyotrophic lateral sclerosis, or ALS. The clinical data from
these initial studies has served as an important confirmation of the underlying immunomodulatory properties of Tregs and their potential therapeutic benefits. These studies have also significantly expanded our own foundational knowledge of the
biological activity of Tregs and key biomarkers of disease progression and drug effect, which we believe will be critical for the design of our future clinical and preclinical studies, the selection of future targeted diseases and the overall
advancement of our development pipeline. We believe our findings have also established mechanistic benefits of combination biologics to address Treg dysfunction as well as highlighted important advantages of scalability and cost. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">COYA 302 is the combination of our proprietary low dose <FONT STYLE="white-space:nowrap">interleukin-2</FONT> (COYA 301, or LD <FONT
STYLE="white-space:nowrap">IL-2)</FONT> and the immunomodulatory drug <FONT STYLE="white-space:nowrap">CTLA4-Ig,</FONT> and we believe this combination has the potential to provide a sustained and durable effect on our first series of indications
(neurodegenerative disorders) through targeting of multiple pathways. Our research and clinical efforts have led us to believe that combination biologics using our LD <FONT STYLE="white-space:nowrap">IL-2</FONT> as a backbone modality could be an
effective way to treat neurodegenerative conditions that are inherently driven by a complexity of pathways. We believe COYA 302 is the most clinically advanced of what we hope will be a family of combination therapies that all feature our LD <FONT
STYLE="white-space:nowrap">IL-2.</FONT> Given the growing list of indications for which we are developing it, we can now refer to COYA 302 as a &#8220;Pipeline in a Product.&#8221; </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently conducting the ALSTARS Trial, a Phase 2, randomized, multi-center,
double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS (ClinicalTrials.gov Identifier: NCT 07161999). COYA 302 is an investigational product not yet approved by the U.S. Food and Drug
Administration, or the FDA, or any other regulatory agency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have consisted of developing our clinical and preclinical
product candidates and we have devoted substantially all of our resources to developing product and technology rights, conducting research and development (which includes preclinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies
of our product candidates), organizing and staffing our company, ongoing business operations and raising capital. We have funded our operations primarily through the private and public sale of our securities. Our net losses were $21.2&nbsp;million
and $14.9&nbsp;million for the years ended December&nbsp;31, 2025 and 2024, respectively. As of December&nbsp;31, 2025, we had an accumulated deficit of $62.0&nbsp;million. Our primary use of cash is to fund operating expenses, which consist
primarily of research and development expenditures and general and administrative expenditures. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual
commercialization of one or more of our current or future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to incur significant expenses and
operating losses for the foreseeable future as we advance our product candidates through all stages of development and clinical trials and, ultimately, seek regulatory approval. In addition, if we obtain marketing approval for any of our product
candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. We expect our expenses and capital requirements will increase significantly in connection with our ongoing
activities as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue our ongoing and planned research and development of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate nonclinical studies and clinical trials for any additional product candidates that we may pursue;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to scale up external manufacturing capacity with the aim of securing sufficient quantities to meet our
capacity requirements for clinical trials and potential commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a sales, marketing and distribution infrastructure to commercialize any approved product candidates and
related additional commercial manufacturing costs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">develop, maintain, expand, protect and enforce our intellectual property portfolio, including patents, trade
secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add clinical, operational, financial and management information systems and personnel, including personnel to
support our product development and planned future commercialization efforts; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur legal, accounting, investor relations and other expenses associated with operating as a public company.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our net losses may fluctuate significantly from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year,</FONT></FONT> depending on the timing of our clinical trials and
our expenditures on other research and development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will need to raise substantial additional capital to support our
continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we plan to finance our operations through the sale of equity, debt financings or other capital sources, which
may include collaborations with other companies or other strategic transactions. There are no assurances that we will be successful in obtaining an adequate level of financing as and when needed to finance our operations on terms acceptable to us or
at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to secure adequate additional funding, we may have to
significantly delay, scale back or discontinue the development and commercialization of one or more product candidates or delay our pursuit of potential <FONT STYLE="white-space:nowrap">in-licenses</FONT> or acquisitions. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Private Placement </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;29,
2026, we entered into the Securities Purchase Agreement with accredited investors for the issuance and sale of 2,522,727 Shares at a price of $4.40 per Share in the Private Placement. The Private Placement closed on January&nbsp;30, 2026. For
additional information regarding the issuances of the Shares, see &#8220;<I>Description of the Transaction</I>&#8221; below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an
Emerging Growth Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as an &#8220;emerging growth company&#8221; as defined in the JOBS Act. An emerging growth company
may take advantage of relief from certain reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced obligations with respect to financial data, including presenting only two years of audited financial
statements and only two years of selected financial data in this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exception from compliance with the auditor attestation requirement of Section&nbsp;404 of the Sarbanes-Oxley
Act of 2002, as amended, or the Sarbanes-Oxley Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and
registration statements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on
executive compensation or golden parachute arrangements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of exemptions for up to five years or
such earlier time that we are no longer an emerging growth company. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock. We would cease to be an emerging
growth company upon the earliest to occur of: (1)&nbsp;the last day of the fiscal year in which we have more than $1.235&nbsp;billion in annual gross revenue, (2)&nbsp;December&nbsp;31, 2026, (3) the date we are deemed to be a &#8220;large
accelerated filer&#8221; as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act, and (4)&nbsp;the date on which we have during the previous three-year period issued more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The JOBS Act also permits us, as an emerging growth company, to take
advantage of an extended transition period to comply with the new or revised accounting standards applicable to public companies and thereby allow us to delay the adoption of those standards until those standards would apply to private companies. We
have elected to avail ourselves of this exemption and therefore, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary
executive offices are located at 5850 San Felipe St., Suite 500, Houston, TX 77057 and our telephone number is (800) <FONT STYLE="white-space:nowrap">587-8170.</FONT> Our website address is www.coyatherapeutics.com. The information contained in, or
accessible through, our website does not constitute a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx206837_4"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Registered shares of common stock offered for resale by the selling stockholders</B> </P></TD>
<TD>2,522,727 Shares, issued in the Private Placement pursuant to the Securities Purchase Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Use of proceeds</B> </P></TD>
<TD>We will not receive any of the proceeds from the sale of Shares by the selling stockholders. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Terms of</B> <B>this</B> <B>offering</B> </P></TD>
<TD>The selling stockholders, including their transferees, donees, pledgees, assignees and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest,</FONT></FONT> may sell, transfer or otherwise dispose of any or all
of the Shares of common stock offered by this prospectus from time to time on The Nasdaq Capital Market or any other stock exchange, market or trading facility on which the shares are traded or in private transactions. The Shares of common stock may
be sold at fixed prices, at market prices prevailing at the time of sale, at prices related to prevailing market price or at negotiated prices. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Risk</B> <B>factors</B> </P></TD>
<TD>Investing in our common stock involves a high degree of risk. See &#8220;<I>Risk Factors</I>&#8221; beginning on page 8 of this prospectus and under similar headings in the other documents that are incorporated by reference in this prospectus
for a discussion of factors to consider before deciding to purchase shares of our common stock. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Capital</B> <B>Market symbol</B> </P></TD>
<TD>Our common stock is currently listed on The Nasdaq Capital Market under the symbol &#8220;COYA.&#8221; </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx206837_5"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before purchasing any of the securities, you should carefully consider the risk factors incorporated by reference in this prospectus from our
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2025, filed with the SEC on March&nbsp;16, 2026 (the &#8220;Annual Report&#8221;), and any subsequent updates described in our Quarterly
Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> as well as the risks, uncertainties and additional information set forth in our SEC reports on Forms <FONT
STYLE="white-space:nowrap">10-K,</FONT> <FONT STYLE="white-space:nowrap">10-Q</FONT> and <FONT STYLE="white-space:nowrap">8-K</FONT> and in the other documents incorporated by reference in this prospectus. For a description of these reports and
documents, and information about where you can find them, see &#8220;<I>Where You Can Find More Information</I>&#8221; and &#8220;<I>Incorporation of Certain Information By Reference</I>.&#8221; Additional risks not presently known or that we
presently consider to be immaterial could subsequently materially and adversely affect our financial condition, results of operations, business and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx206837_6"></A>DESCRIPTION OF THE TRANSACTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;29, 2026, we entered into the Securities Purchase Agreement with certain accredited investors for the issuance and sale of
2,522,727 Shares at a price of $4.40 per Share in the Private Placement. The Shares were issued pursuant to an exemption from registration under Section&nbsp;4(a)(2) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;),
and/or Rule 506 of Regulation D, which is promulgated under the Securities Act. We relied on this exemption from registration based in part on representations made by the accredited investors in the Securities Purchase Agreement. Pursuant to the
Securities Purchase Agreement, we are required to file a registration statement with the SEC covering the resale of the securities issued in the Private Placement no later than 45 days after the date of Closing (as defined below), and to have such
registration statement declared effective as promptly as possible but in any event no later than 75 days after the date of Closing, subject to extension under the terms of the Securities Purchase Agreement. The registration statement of which this
prospectus forms a part is being filed to satisfy such obligations under the Securities Purchase Agreement. The Private Placement closed on January&nbsp;30, 2026 (the &#8220;Closing&#8221;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx206837_7"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of common stock being offered by the selling stockholders under this prospectus or their permitted transferees are those previously
issued to the selling stockholders. For additional information regarding the issuances of the Shares, see &#8220;<I>Description of the Transaction</I>&#8221; above. We are registering the shares of common stock in order to permit the selling
stockholders or their permitted transferees to offer the shares for resale from time to time. The term &#8220;selling stockholders&#8221; includes the stockholders listed in the table below and their permitted transferees. Except for the ownership
of our common stock and as described below, the selling stockholders have not had any material relationship with us within the past three years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2023, we entered into a Development and License Agreement, or the DRL Development Agreement, with Dr.&nbsp;Reddy&#8217;s
Laboratories SA (&#8220;Dr.&nbsp;Reddy&#8217;s&#8221;), the parent company of Dr.&nbsp;Reddy&#8217;s Inc. (as defined below), the acquiror of 2,272,727 shares as indicated in the below table, pursuant to which, among other things, we granted to
Dr.&nbsp;Reddy&#8217;s an exclusive, royalty-bearing right and license to commercialize COYA 302 solely for use in patients with ALS in the United States, Canada, the European Union and the United Kingdom, or collectively, the New Territories. We
previously granted Dr.&nbsp;Reddy&#8217;s Laboratories Ltd an exclusive license to obtain regulatory approval and commercialize COYA 302 for ALS and certain other indications in all other countries (other than the New Territories, Japan, Mexico, and
in each country in South America), pursuant to the License and Supply Agreement entered into with Dr.&nbsp;Reddy&#8217;s Laboratories Ltd, or the DRL Agreement, effective as of April&nbsp;1, 2023. In accordance with the DRL Agreement, we <FONT
STYLE="white-space:nowrap">in-licensed</FONT> DRL_AB for the development and commercialization of COYA 302. Further, under the DRL Development Agreement, Dr.&nbsp;Reddy&#8217;s is responsible for the development of DRL_AB. We will have the
responsibility for the clinical development of COYA 302 and for seeking regulatory approval in the United States for COYA 302 in ALS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
collaboration is managed by a joint steering committee, or JSC, which is comprised of representatives from both parties. Decisions of the JSC are made by consensus. If the JSC is unable to reach a consensus, and the parties&#8217; executives are not
able to resolve the dispute, then Dr.&nbsp;Reddy&#8217;s has final decision-making authority, subject to specified limitations (as set forth in the DRL Development Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the DRL Development Agreement, we received an <FONT STYLE="white-space:nowrap">up-front,</FONT> nonrefundable payment of
$7.5&nbsp;million in January 2024. Additionally, we are entitled to receive (i)&nbsp;an additional $4.2&nbsp;million upon FDA acceptance of an IND application for COYA 302 for the treatment of ALS and (ii)&nbsp;an additional $4.2&nbsp;million
payment upon the dosing of the first patient in the first phase 2 clinical trial for COYA 302 for the treatment of ALS in the United States. The DRL Development Agreement also calls for up to an aggregate of $40.0&nbsp;million in development
milestones and up to an aggregate of $677.3&nbsp;million in sales milestones, related to the New Territories, should all such development and sales milestones be achieved. We will also be owed royalties by Dr.&nbsp;Reddy&#8217;s on Net Sales (as
defined in the DRL Development Agreement) of COYA 302 in the low to <FONT STYLE="white-space:nowrap">mid-teens</FONT> (prior to paying royalties due pursuant to previously disclosed license agreements related to COYA 302). In June 2024, we entered
into the First Amendment to the DRL Development Agreement, or the First Amendment, with Dr.&nbsp;Reddy&#8217;s, pursuant to which, among other things, Dr.&nbsp;Reddy&#8217;s paid us a <FONT STYLE="white-space:nowrap">one-time</FONT> payment of
$3.9&nbsp;million and, in return, Dr.&nbsp;Reddy&#8217;s will have no obligation to pay the first $6.0&nbsp;million in royalty payments that would have otherwise been payable to us under the DRL Development Agreement. Pursuant to the First
Amendment, as discussed above, the first $6.0&nbsp;million of royalty payments will not be owed to us. On December&nbsp;16, 2025, we received a $4.2&nbsp;million milestone payment under the DRL Development Agreement, which was triggered by dosing of
the first patient in our ALSTARS trial evaluating COYA 302 for the treatment of ALS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below lists the selling stockholders and
other information regarding the beneficial ownership of the shares of common stock by each of the selling stockholders. The second column lists the number of shares of common stock beneficially owned by each selling stockholder, including its
ownership of the Shares, as of March&nbsp;10, 2026. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The third column lists the Shares of common stock being offered under this prospectus by the
selling stockholders. This prospectus generally covers the resale of the number of Shares issued to the selling stockholders in the Private Placement as described above under &#8220;<I>Description of the Transaction</I>&#8221; as of the trading day
immediately preceding the applicable date of determination. The fourth column assumes the sale of all of the Shares offered by the selling stockholders pursuant to this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may sell all, some or none of their Shares in this offering. See &#8220;<I>Plan of Distribution</I>.&#8221; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Selling Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares of<BR>Common<BR>Stock&nbsp;Owned</B><br><B>Prior&nbsp;to&nbsp;Offering&nbsp;(1)<BR>(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>Number of</B><br><B>Shares of<BR>Common&nbsp;Stock</B><br><B>to be Sold<BR>Pursuant to</B><br><B>this Prospectus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares of<BR>Common<BR>Stock<BR>Owned</B><br><B>After<BR>Offering<BR>(1) (2) (3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent of<BR>Shares of<BR>Common<BR>Stock&nbsp;Owned</B><br><B>After&nbsp;Offering<BR>(4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Greenlight Capital (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,335,540</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,085,540</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Reddy&#8217;s Laboratories, Inc. (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,272,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,272,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1% </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as noted below, ownership is determined in accordance with the rules of the SEC and generally includes
voting or investment power with respect to securities. All entries exclude ownership of shares issuable pursuant to warrants, options or other derivative securities that have not vested or that are not otherwise exercisable as of the date hereof or
which will not become vested or exercisable within 60 days of March 10, 2026. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based upon our internal books and records and public filings only, as of the date of this prospectus; may not
include ownership of shares of our common stock, if any, held in &#8220;street name&#8221; through unrelated third-party brokers, as of the date of this prospectus, which are not being offered for resale by this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The difference between the number of shares of common stock owned prior to the offering and the maximum number
of shares of common stock to be sold pursuant to this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All percentage calculations are based on 23,457,183 shares of our common stock outstanding as of March 10, 2026
and are rounded to the nearest tenth of a percent. Warrants, options or other derivative securities that are presently exercisable or exercisable within 60 days are deemed to be owned by the person holding such securities for the purpose of
calculating the percentage ownership of that person but are not treated as outstanding for the purpose of calculating the percentage ownership of any other person. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents shares to be sold for the accounts of Malachite Partners, LLC (&#8220;Malachite&#8221;), Greenlight
Capital Offshore Master, Ltd. (&#8220;GCOM&#8221;), a <FONT STYLE="white-space:nowrap">sub-account</FONT> for a private partnership <FONT STYLE="white-space:nowrap">(&#8220;Sub-Account&#8221;),</FONT> and a managed account (the &#8220;Managed
Account&#8221;). DME Capital Management, LP d/b/a Greenlight Capital (&#8220;DME Management&#8221;) is the investment advisor for (a)&nbsp;Malachite, and as such has voting and dispositive power over the 1,428,373 shares of common stock held by
Malachite, (b)&nbsp;GCOM, and as such has voting and dispositive power over the 702,747 shares of common stock held by GCOM, (c)&nbsp;the <FONT STYLE="white-space:nowrap">Sub-Account,</FONT> and as such has voting and dispositive power over the
101,330 shares of common stock held by the <FONT STYLE="white-space:nowrap">Sub-Account,</FONT> and (d)&nbsp;the Managed Account, and as such has voting and dispositive power over the 103,090 shares of common stock held by the Managed Account. DME
Advisors GP, LLC (&#8220;DME GP&#8221;) is the general partner of DME Management, and as such has voting and dispositive power over the 2,335,540 shares of common stock held by Malachite, GCOM, the <FONT STYLE="white-space:nowrap">Sub-Account</FONT>
and the Managed Account. David Einhorn is the principal of DME Management and DME GP, and as such has voting and dispositive power over the 2,335,540 shares of common stock held by Malachite, GCOM, the
<FONT STYLE="white-space:nowrap">Sub-Account</FONT> and the Managed Account. Each of DME Management, DME GP and Mr.&nbsp;Einhorn disclaims beneficial ownership of these shares of common stock, except to the extent of any pecuniary interest therein.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes certain shares of our common stock which are not being offered pursuant to this prospectus.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Reddy&#8217;s Laboratories, Inc. (&#8220;Dr.&nbsp;Reddy&#8217;s Inc.&#8221;) has voting and investment
control over the common stock. The board of directors of Dr.&nbsp;Reddy&#8217;s Inc. is composed of four (4)&nbsp;individuals, none of whom has </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
sole decision power. Because voting and dispositive decisions are made by a majority of the board, none of the board members of Dr.&nbsp;Reddy&#8217;s Inc. is deemed to be a beneficial owner of
the shares. The business address of Dr.&nbsp;Reddy&#8217;s Inc. is 600 College Road East, Suite 4000, Princeton, NJ 08540. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of our
common stock by the selling stockholders or their permitted transferees, if any, will not affect the rights or privileges of our other existing stockholders because our total outstanding shares of common stock will not change as a result of any such
sales by the selling stockholders identified herein or their permitted transferees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx206837_8"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Shares to be offered and sold using this prospectus will be offered and sold by the selling stockholders named in this prospectus.
Accordingly, we will not receive any proceeds from any sales of the Shares in this offering. We will pay all of the fees and expenses incurred by us in connection with this registration. We will not be responsible for fees and expenses incurred by
the selling stockholders or any underwriting discounts or agent&#8217;s commissions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx206837_9"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each selling stockholder of the securities and any of their pledgees, assignees and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> may, from time to time, sell any or all of their securities covered hereby on The Nasdaq Stock Market or any other stock exchange, market or trading facility on which the securities are
traded or in private transactions. These sales may be at fixed or negotiated prices. A selling stockholder may use any one or more of the following methods when selling securities: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell
a portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">settlement of short sales; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in transactions through broker-dealers that agree with the selling stockholders to sell a specified number of
such securities at a stipulated price per security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if
available, rather than under this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Broker-dealers engaged by the selling stockholders may arrange for other brokers-dealers to
participate in sales. Broker-dealers may receive commissions or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set
forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with
FINRA Rule 2121. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sale of the securities or interests therein, the selling stockholders may enter into hedging
transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The selling stockholders may also sell securities short and deliver these
securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions with broker-dealers or other
financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial
institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders and
any broker-dealers or agents that are involved in selling the securities may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such
broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
selling stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company
has agreed to indemnify the selling stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We agreed to keep the registration statement of which this prospectus forms a part effective until the earlier of (i)&nbsp;the date on which
the securities may be resold by the selling stockholders without registration and without regard to any volume or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> limitations by reason of Rule 144,
without the requirement for the Company to be in compliance with the current public information requirement under Rule 144 under the Securities Act or any other rule of similar effect or (ii)&nbsp;all of the securities have been sold pursuant to
this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in
certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not
simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the selling stockholders will be subject
to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by the selling stockholders or any other person. We will make copies
of this prospectus available to the selling stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx206837_10"></A>DESCRIPTION OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following summary of the rights of our capital stock is not complete and is subject to and qualified in its entirety by reference to
our Amended and Restated Certificate of Incorporation, Amended and Restated Bylaws, copies of which are filed as exhibits to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2025, and forms
of securities, copies of which are filed as exhibits to the registration statement of which this prospectus forms a part, which are incorporated by reference herein. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock
consists of 200,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;10, 2026, there were 23,457,183 shares of common stock outstanding and no shares of preferred stock outstanding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of shares of our
common stock are entitled to one vote for each share held of record on all matters on which stockholders are entitled to vote generally, including the election or removal of directors elected by our stockholders generally. The holders of our common
stock do not have cumulative voting rights in the election of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of shares of our common stock are entitled to receive
dividends when, as and if declared by our board of directors out of funds legally available therefor, subject to any statutory or contractual restrictions on the payment of dividends and to any restrictions on the payment of dividends imposed by the
terms of any outstanding preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon our liquidation, dissolution or winding up and after payment in full of all amounts
required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, the holders of shares of our common stock will be entitled to receive our remaining assets available for distribution on a pro rata basis.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All shares of our common stock are fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> The shares of our common stock
are not subject to further calls or assessments by us. Holders of shares of our common stock do not have preemptive, subscription, redemption or conversion rights. There are no redemption or sinking fund provisions applicable to the common stock.
The rights powers, preferences and privileges of our common stock are subject to those of the holders of any shares of our preferred stock or any other series or class of stock we may authorize and issue in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors
has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more classes or series. Our board of directors is able to determine, with respect to any series of preferred stock, the
powers (including voting powers), preferences and relative, participating, optional or other special rights, and the qualifications, limitations or restrictions thereof, including, without limitation: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of the series, which our board of directors may, except where otherwise provided in the
preferred stock designation, increase (but not above the total number of authorized shares of the class) or decrease (but not below the number of shares then outstanding); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether dividends, if any, will be cumulative or <FONT STYLE="white-space:nowrap">non-cumulative</FONT> and the
dividend rate of the series; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates at which dividends, if any, will be payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the redemption or repurchase rights and price or prices, if any, for shares of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and amounts of any sinking fund provided for the purchase or redemption of shares of the series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amounts payable on shares of the series in the event of any voluntary or involuntary liquidation, dissolution
or <FONT STYLE="white-space:nowrap">winding-up</FONT> of our affairs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the shares of the series will be convertible into shares of any other class or series, or any other
security, of us or any other entity, and, if so, the specification of the other class or series or other security, the conversion price or prices or rate or rates, any rate adjustments, the date or dates as of which the shares will be convertible
and all other terms and conditions upon which the conversion may be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the issuance of shares of the same series or of any other class or series; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the voting rights, if any, of the holders of the series. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could issue a series of preferred stock that could, depending on the terms of the series, impede or discourage an acquisition attempt or
other transaction that some, or a majority, of the holders of our common stock might believe to be in their best interests or in which the holders of our common stock might receive a premium over the market price of the shares of our common stock.
Additionally, the issuance of preferred stock may adversely affect the rights of holders of our common stock by restricting dividends on the common stock, diluting the voting power of the common stock or subordinating the liquidation rights of the
common stock. As a result of these or other factors, the issuance of preferred stock could have an adverse impact on the market price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws and Certain Provisions of Delaware Law
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation (&#8220;Amended Charter&#8221;), amended and restated bylaws (&#8220;Amended
Bylaws&#8221;) and the Delaware General Corporation Law (the &#8220;DGCL&#8221;) contain provisions that are intended to enhance the likelihood of continuity and stability in the composition of our board of directors. These provisions are intended
to avoid costly takeover battles, reduce our vulnerability to a hostile or abusive change of control and enhance the ability of our board of directors to maximize stockholder value in connection with any unsolicited offer to acquire us. However,
these provisions may have an anti-takeover effect and may delay, deter or prevent a merger or acquisition of our company by means of a tender offer, a proxy contest or other takeover attempt that a stockholder might consider in its best interest,
including those attempts that might result in a premium over the prevailing market price for the shares of common stock held by stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential Effects of Authorized but Unissued Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our Amended Charter, we have shares of common stock and preferred stock available for future issuance without stockholder approval.
We may utilize these additional shares for a variety of corporate purposes, including future public offerings to raise additional capital, to facilitate corporate acquisitions or payment as a dividend on the capital stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The existence of unissued and unreserved common stock and preferred stock may enable our board of directors to issue shares to persons
friendly to current management or to issue preferred stock with terms that could render more difficult or discourage a third-party attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the
continuity of our management. In addition, the board of directors has the discretion to determine designations, rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and
liquidation preferences of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
each series of preferred stock, all to the fullest extent permissible under the DGCL and subject to any limitations set forth in our Amended Charter. The purpose of authorizing the board of
directors to issue preferred stock and to determine the rights and preferences applicable to such preferred stock is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing
desirable flexibility in connection with possible financings, acquisitions and other corporate purposes, could have the effect of making it more difficult for a third-party to acquire, or could discourage a third-party from acquiring, a majority of
our outstanding voting stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Combinations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the DGCL, which prohibits a Delaware corporation from engaging in any business combination with any
interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before such date, the board of directors of the corporation approved either the business combination or the
transaction that resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the
interested stockholder) those shares owned (i)&nbsp;by persons who are directors and also officers and (ii)&nbsp;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the
plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or after such date, the business combination is approved by the board of directors and authorized at an annual
or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines &#8220;business combination&#8221; to include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the
interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any
stock of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock
or any class or series of the corporation beneficially owned by the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other
financial benefits by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an &#8220;interested
stockholder&#8221; as an entity or person who, together with the person&#8217;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the
outstanding voting stock of the corporation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Cumulative Voting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Delaware law, the right to vote cumulatively does not exist unless the certificate of incorporation specifically authorizes cumulative
voting. Our Amended Charter does not authorize cumulative voting. Therefore, stockholders holding a majority of the shares of our stock entitled to vote generally in the election of directors will be able to elect all our directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Stockholder Meetings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Amended Charter provides that special meetings of our stockholders may be called at any time only by or at the direction of the board of
directors, the chairman of the board of directors or our chief executive officer. Our Amended Bylaws prohibit the conduct of any business at a special meeting other than as specified in the notice for such meeting. These provisions may have the
effect of deferring, delaying, or discouraging hostile takeovers, or changes in control or management of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Nominations and
Stockholder Proposals </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Amended Bylaws establish advance notice procedures with respect to stockholder proposals and the nomination
of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. In order for any matter to be &#8220;properly brought&#8221; before a meeting, a
stockholder will have to comply with advance notice requirements and provide us with certain information. Generally, to be timely, a stockholder&#8217;s notice must be received at our principal executive offices not less than 90 days nor more than
120 days prior to the first anniversary date of the immediately preceding annual meeting of stockholders. However, in the event that the date of the annual meeting is more than 30 days before or more than 70 days after the anniversary date, notice
by the stockholder must be delivered not earlier than the close of business on the 120th day prior to the annual meeting and not later than the close of business on the later of the 90th day prior to the annual meeting or the 10th day following the
day on which public announcement of the date of the meeting is first made by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Amended Bylaws also specify requirements as to the
form and content of a stockholder&#8217;s notice. Our Amended Bylaws allow the chairman of the meeting at a meeting of the stockholders to adopt rules and regulations for the conduct of meetings that may have the effect of precluding the conduct of
certain business at a meeting if the rules and regulations are not followed. These provisions may also defer, delay, or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or
otherwise attempting to influence or obtain control of the company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment of Our Amended Charter or Amended Bylaws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a
corporation&#8217;s certificate of incorporation or bylaws, unless a corporation&#8217;s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. Our Amended Bylaws may be amended or repealed by a majority vote of
our board of directors or by the affirmative vote of the holders of at least 66 2/3% of the votes which all our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least
66 2/3% of the votes which all our stockholders would be entitled to cast in any election of directors will be required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our certificate described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing provisions of our Amended Charter and Amended Bylaws could discourage potential acquisition proposals and could delay or prevent
a change in control. These provisions are intended to enhance the likelihood of continuity and stability in the composition of our board of directors and in the policies formulated by our board of directors and to discourage certain types of
transactions that may involve an actual or threatened change of control. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be
used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they also may inhibit fluctuations in the market price of our shares of common stock that
could result from actual or rumored takeover attempts. Such provisions also may have the effect of preventing changes in our management or delaying or preventing a transaction that might benefit you or other minority stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dissenters&#8217; Rights of Appraisal and Payment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, with certain exceptions, our stockholders will have appraisal rights in connection with a merger or consolidation of us.
Pursuant to the DGCL, stockholders who properly request and perfect appraisal rights in connection with such merger or consolidation will have the right to receive payment of the fair value of their shares as determined by the Delaware Court of
Chancery. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholders&#8217; Derivative Actions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, any of our stockholders may bring an action in our name to procure a judgment in our favor, also known as a derivative action,
provided that the stockholder bringing the action is a holder of our shares at the time of the transaction to which the action relates or such stockholder&#8217;s stock thereafter devolved by operation of law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Choice of Forum </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Amended Charter
provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any stockholder to bring (i)&nbsp;any derivative action or proceeding
brought on behalf of the Company, (ii)&nbsp;any action asserting a claim of breach of fiduciary duty owed by any current or former director, officer or other employee of the Company or the Company&#8217;s stockholders, (iii)&nbsp;any action
asserting a claim against the Company or any director or officer of the Company arising pursuant to, or a claim against the Company or any director or officer of the Company, with respect to the interpretation or application of any provision of, the
DGCL, our Amended Charter or Amended Bylaws, or (iv)&nbsp;any action asserting a claim governed by the internal affairs doctrine, except for, in each of the aforementioned actions, any claims to which the Court of Chancery of the State of Delaware
determines it lacks jurisdiction. This provision does not apply to claims arising under the Exchange Act, or for any other federal securities laws which provide for exclusive federal jurisdiction. However, the exclusive forum provision provides that
unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America is the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities
Act. Therefore, this provision could apply to a suit that falls within one or more of the categories enumerated in the exclusive forum provision and that asserts claims under the Securities Act, inasmuch as Section&nbsp;22 of the Securities Act
creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. There is uncertainty as to whether a court would enforce such
an exclusive forum provision with respect to claims under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We note that there is uncertainty as to whether a court
would enforce the provision and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Although we believe this provision benefits us by providing increased consistency in the application of
Delaware law in the types of lawsuits to which it applies, the provision may have the effect of discouraging lawsuits against our directors and officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
transfer agent and registrar for shares of our common stock is Computershare Trust Company, N.A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx206837_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the securities offered hereby will be passed upon for us by Lowenstein Sandler LLP, New York, New York. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx206837_12"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of Coya Therapeutics, Inc. as of December&nbsp;31, 2025 and 2024, and for each of the two years in the period ended
December&nbsp;31, 2025, incorporated in this prospectus by reference to the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2025, have been audited by Weaver and Tidwell, L.L.P., an independent
registered public accounting firm, as stated in their reports. Such financial statements are incorporated by reference in reliance upon the report of such firm given their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx206837_13"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the informational requirements of the Exchange Act and in accordance therewith file annual, quarterly and current reports,
proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of the
SEC&#8217;S website is www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We make available free of charge on or through our website our Annual Reports on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and amendments to those reports filed or furnished pursuant to
Section&nbsp;13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after we electronically file such material with or otherwise furnish it to the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement under the Securities Act, relating to the offering of these securities. The registration
statement, including the attached exhibits, contains additional relevant information about us and the securities. This prospectus does not contain all of the information set forth in the registration statement. You can obtain a copy of the
registration statement for free at www.sec.gov. The registration statement and the documents referred to below under &#8220;<I>Incorporation of Certain Information By Reference</I>&#8221; are also available on our website, <FONT
STYLE="white-space:nowrap">https://ir.coyatherapeutics.com/financials/sec-filings/default.aspx.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not incorporated by
reference into this prospectus the information on our website, and you should not consider it to be a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx206837_14"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following documents filed with the SEC are incorporated by reference into this prospectus: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2025,
filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1835022/000119312526107281/coya-20251231.htm">March&nbsp;16, 2026</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1835022/000119312526007042/d39008d8k.htm">January
<U></U>&nbsp;8, 2026</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1835022/000119312526016017/d48170d8k.htm">January<U></U>&nbsp;
20, 2026</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1835022/000119312526030531/d88735d8k.htm">January<U></U>&nbsp;30, 2026</A> (other than any portion thereof deemed furnished and not filed); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in <A HREF="http://www.sec.gov/Archives/edgar/data/1835022/000095017024033161/coya-ex4_7.htm">Exhibit
 4.7</A> to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;
31, 2023, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1835022/000095017024033161/coya-20231231.htm">March<U></U>&nbsp;19, 2024</A>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference all documents we file pursuant to Section&nbsp;13(a), 13(c), 14 or 15 of the Exchange Act (other than any
portions of filings that are furnished rather than filed pursuant to Items 2.02 and 7.01 of a Current Report on Form <FONT STYLE="white-space:nowrap">8-K)</FONT> after the date of the initial registration statement of which this prospectus is a part
and prior to effectiveness of such registration statement. All documents we file in the future pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus and prior to the termination of the offering are
also incorporated by reference and are an important part of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained in a document incorporated or deemed
to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is or deemed
to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral
request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits which are specifically incorporated by reference into such documents. You can request a
copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Coya Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5850 San Felipe St., Suite 500 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Houston, Texas 77057 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(800) <FONT
STYLE="white-space:nowrap">587-8170</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Copies of these filings are also available, without charge, on the SEC&#8217;s website at
www.sec.gov and on our website at www. https://coyatherapeutics.com as soon as reasonably practicable after they are filed electronically with the SEC. The information contained on our website is not a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>2,522,727 Shares of Common
Stock </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g206837g12p03.jpg" ALT="LOGO" STYLE="width:2.13986in;height:0.893806in;">
 </P> <P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Coya Therapeutics, Inc. </B></P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>March 20, 2026 </B></P>
<P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g206837g12p03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g206837g12p03.jpg
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M 0 " P$!                ! (#!0$&_\0 -1$  @(! P,"! ,'! ,
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ME&-JI ;M0@0U(/-_WLGYP''O!5>KTZ@M\%V)Z+4N;<)ON6$B(D#1"(B "(B
M"(OR1[8XW/D<&L:"7.<<  =90!$=J6M(=$:7EKRUDM;(>BI87\GO/6<<< <3
M\W6J._\ R&U+_P!-M'Z$G[ZB>V+6CM9ZMEF@>?8RES#2-ZBW/%_K<1GU8'4H
M*M>C2Q4/C7<QK]7-S>QX1=$/E ZIFE9%#:K2^1[@UK6QR$N)X  ;ZZ/L+[A)
M9Z-]Z; RXOC#IV0 AC''CNC))X<LY7.GDVZ(]D[L_4MPBS1T+MVE#AP?-]]Z
MF@_.1V+II)ZO9&6R"X'='U)1WS?(1$2@X$1$ $1$ $<0T$N( '$D]2*M=OVJ
M_:YH>:GIY-VON>::+!XM9CW1WS</6X*<(.<E%$+)J$7)^"%,V]S.UR*,TM&-
M.FKZ'SC#NEZ/.[TF=['];ER5_@@@$'(*_GRNP-@VJO;+H6GCJ)-ZOMV*6;)X
MN 'H.\6\/6"G=7IXPBI00CH]3*R3C-EC(B+/-$(B( (B( (B( (B( (B( *E
MML>V".Q&>RZ8D9-=!ED]4,.93GL'47_0.\\FWC:@;%%)I^P38NLC?^(G8?\
MX[2/>C^N1\P[R,<Q$DDDG)/,E:&ETN[XY\&;J]7M^"')ZU53-5U,M153233R
MN+GR2.+G.)YDD\UY(K&V8;*KIK1[:N<NH+*#QJ7M]*7M$8Z_7R'?R6C.<:UF
M7!FPA*QXCW9 K=05=RK(Z6W4TU54R'#8H6%SCX!7#I#8#=Z]K)]1UD=LA/'H
M(P)92._XK?G/J5^Z0TA9=)4/FUDHF0Y&))G>E+)WN=S/JY=@6_6;;KI/M#L:
ME6@BN]G<K_3^Q_1MF:T^Q8KI1SDK7=+G\WWOT*;T5!1T$8CH:2GIHQR;#&&#
MY@%DHDI3E+YGD=C7&'RK 1$429XU5+3U<9CJH(IHSS;(P.!\"H??ME>CKRUW
M3V2GIY3_ ,RD]Q([\-X'Q!4V12C.4?E>",H1E\RR<YZL\GJHA:^;2US%0!Q%
M-6 -=X/' GU@>M4O?[%=-/USJ.]4,]'4#DV5N X=K3R([PN]%K=06*V:@M[Z
M&\T4-73.^+(.+3VM/,'O"<JULX]I]T)6Z"$N\.S."UZTM1-25$=12RR0SQN#
MF21N+7-(Y$$<BK9VJ;&JW3;)KGI\RU]H;ESXR,RTX[\>^;WCEUCK50K2A9&Q
M9B9=E<JI8D=.[&MK[+\Z&R:GD9'=3Z,%3[UM1_5/4'_0?7SNE?SZ:XM<'-)#
M@<@CJ746P;:8=14S;#?)LWB!GN,SSQJ6#M_K@<^T<>U9^JTNWXX<&EI-7N^"
M?)<:(BSS1"(B -'JW55GTG;Q67VL;3QN.[&T N?(>QK1Q/U!1"GUOI#:;;:_
M3<-;+!/6Q.C;'/'N.)YAS>HD$ XSG@JD\J UGM\I14;WF@HF>;_>^^=O>.>?
M@JML1JQ>K>;;O^?"HCZ#<Y])O#=QXX6C3I(RK4\]S,NUDHV.&.Q.[CL5UI2W
M-U+3VZ.KAWL,J8YV!CAVG>((]1'SKH79!H<Z&TRZDJ)635]3)TU0]GO0<8#6
M]H Z^TE3@9P,\^O"^99&11/DE>UD;!O.<XX ':4M;J9VQVL:JTM=,MR/I1^\
MZOM%IJC35,[GSM]\R)N]N^O_ $7Q#K6Q2U7F[:T!Q. ]S'!A/K*INYLGCN-4
MRKSYP)';^>LYXE<JJW/XA+7>H]**=+3S^>"PMHE_96Z>I'6FHWZ6HD<V5S<@
M\!G=/9SSCN5>6VLGH*V&II'N9-&X%I'7W>HJ8[-K0R[4ET@KHW.H7[@!Y8D&
M<%I[0#]*E5GT%:[=6LJ2^>I>P[S&RD;K3U' '%6*<:TXB+TVHUTHZA=L_P L
M?YD@6N[16TE]JJF2&1T%2_I62 $CCQW<]HY+;:'TO55EINIJFOIXJJ$11;XQ
MD@AP=CLR!]*M1%4[WMP:$?2JU:[&\IY[?<I$:*OOGGF_F1YXZ3>&YCMS_P"E
M;W6NDZNGMML=0L?5,I8.AE#!D@Y+MX#L))5HHCKRRF$?2:8PE%-]_P"146SZ
MQ7#V9CN$E-+%!3!SLO:6[[MT@-&>?-16XUU37ULE35RO?,]V22>7<.P+H=1B
MXZ&LU=7.JGQRQ/>=Y[8GX:X^K'#PPIQO6YN0M?Z5)51KJ?G+R8VB[\&:/967
MJHW&12&(2R')>!R[R>8\%N[-J&V7E[V6^J;)(T9+"TM=CMP>:ANU"UOIK5;1
M00[E!3;S7,8.#"<8)^8\>_O4:V>P3OU+33Q99#3[TDTAX-:S!SD]ZYTXRBYD
MEK+=/=#3-9X6??ZEV*B?*ATU65M%;;[1Q/EAHVNAJ0T9+&D@M?ZLY!/>%:U+
MK&R55<*6*L'2..ZUSF$-<>P$K?N:'-+7 %I&"#R(4*YRIFI8-.73U,'&,L_8
M_GTNG_)CTU66G3UQNM=$^'V3='T+'C!,; [#\=A+SCN&>M6(S0NE65WGC-/6
ML5&=[>\V;P/;C&,J1@8&!R3-^KZD=J11I]'TI[Y,(M=:+Y:[PZI;:KA2UCJ9
M_1S"&0/W'=AQZC\RV*2:QR/)I]T%S]Y2^A\M9JNW1<1NQ5S6CJY,D^II_-[U
MT"O"OHX+A13T=9$V6FG88Y(W<G-(P0K*;'5-217=4K8.+. %*=FFK9]&:KI;
ME'O.IB>BJHA_S(B>/B.8[POG:1I.?1NJJJUS;SH,])32D?PD1)W3Z^8/>"HP
MMSX;(_1F!\5<OJC^@%#5P5]'!5T<K9:>=@DCD:>#FD9!7LJ \FC7&_&_2ERE
M])N9:%SCS'-T?UN'YW<K_6';6ZI.+-^FU6P4D$1%46A$1 !4QY1^M_8BRMT[
M;Y<5UP9FH+3QC@SC'K<>'J![5:>J+Y2:<L-;=K@[%/31EY YN/(-'>3@>*X@
MU->ZO45]K;K<'[U14R%Y'4T=31W 8 ]2<T=.^6Y\(1UM^R.Q<LUBVVE+#5ZE
MU!16FWMS/4O#=XC@QO-SCW 9*U*ZC\G+1'L+877^OBQ<+BP="'#C'!S'B[@?
M5NK1OMZ4,^3-T]+NGM\%HZ<LU)I^QT=JMS-RFI8PQO:[M<>\G)/K6R1%AMY>
M6;Z22P@B(N'0B(@ B(@ N.=N&J_;1KFJ,$F]04/_  M/@\#ND[SO%V>/8 NB
M]M.JO:IH:KF@DW:^K_X6FP>(<X'+O!N3Z\+C1:6AJYL9F>H6\5H*QM@VJO:U
MKJGCJ)-V@N.*6;)X D^@[P=P]3BJY0'!R.!3\X*<7%^3.KFX24EX/Z#(H7L@
MU3[;-#T59*_>K8!YM5=O2- XGUC#O%318$HN+<7X/10DIQ4EY"(BB2"(B "(
MB "(B "A&US6\>B=+OJ(RUUSJ<Q4<9X^ECB\CL;S]>!UJ;/<UC2YY#6M&22<
M !<7;7-7/UAK&JJXWDT$!,%(WJZ,$^EZW')\0.I,Z6GJS[\(5U=_2AVY9$*J
MHFJZF6HJ97RSRN+Y)'G)<XG))*\D4_V-:$?K74@%2UPM%'B2J>.&]V1@]IQX
M 'N6Q*2A'<^$8L(.R6U<LDFQ'92=1OCOFH8G-LS'9AA/ U1!YG^H/I74$,4<
M$+(H&-CB8T-:Q@P&@<@!U!?E-!%34\<%/&R*&)H8QC!@-:!@ #L7HL2ZZ5LL
MLWJ*(TQP@B(J2X(B( (B( (B( (B( 'B,%<\;<MDK((ZC46EJ?=C&7UE%&.#
M1UR,'9VCQ"Z'0C(P>2MJME5+=$JNIC;';(_GW&Q\DC61M<][B&M:T9))Z@%T
M+L;V.5-)5T>H-4&2GGA<V:FHF.+7M(XATA'+\4>/6%9NG=FVF[!J&LO-#1#S
MR=Y?&'X+*?/,1CXN3GU9P,!3)-7ZQR6V'84T^A4'NL[A$1(&@%6NTC:[:=&5
M_L<VFEN-R:T.DBC>&-B!&1O..>)'' !X*REQEMJM-;:]H]Z-<Q^[53NJ()".
M#XW<1@]WO?!,Z6J-L\2%=7;*J&8EXV34>D-L]&^UW6WR05].#*R)[_3:.1=&
M\<^K(([.!4AT;LJTQI2X"OH*::>M;_!S54F^8_Q0  #WXRJ$\G.TUM;M'I*Z
MF8\4E"R1]1(!Z(#F.:&Y[23R[B>I=;*6HS5+9!]B.EQ='J37?W"B6T>1\VDZ
MGS.0/:V1G2[ASZ.>[OPM/M9NM3!YK;X'NCAE89)"TXW^. /4J^ME?/;JMD].
M[!'!S3[U[>MKAU@J%53:4A#7>HQC*6GQ]&S$5SV33U%<M/VR2\T3):H0M!<[
M(=CXH)'$\,<UE4>E+&V6.LCMT;9" \-<26@\_>DX4@7++MWREFA]-=+;MP\^
M/_IXTE+!1T[8*6)D,+>3&# "]D6+-<:*"LBI)JRFCJI>,<+Y6A[_ %-)R53R
M:RQ%8,I%1UZV\"W:WGM8M+7VNFJ332S&0B4D.W7. Y8!!X=?:%#=1ZXUU3[6
MIZ2GJ*MKXZ[H8+>T'HI(M[#1N\B"W!WN_.0F(Z2;Y[=LBTM96N._?!U&BY.U
M@_7?W6JKS<W3S_SP^9B/>Z/HM[T-WXNYNXSU<\]:R-?Z^UM0[2ZVGIZVJIW4
MU3T5/11@]&]F?1]#X^\,'CV\%-:-O&)+C)!ZU+.8OL\'5**@=4;>:ZTZKFH(
M+/3/HZ23H:@2/=TKGM.'[I!P..0,@\E=%-J2SSS4M.+G1LK*F-LL=,^=K92'
M#(]#.>15$Z9P2;7)?"^$VU%\&V(#@00"#S!6FU+;GU&FZ^DMT;8Y9(_1:P!N
M\<Y(\0,>*W**M/#R3G!3BXOSV.>Z2UUU57-I(::;S@NW=TM(+?7V*^8JNFA=
M%235<!J@T L,@#G''/'->M:96T=0:89G$;C&.UV#CZ5SQ,^5T[WS.>9BXEQ<
M?2SW]Z97[?Z8,-X]*X^)R_+@Z-0C((/(K6Z9?4R6"@?6[WG!A:7[W,\.OOPM
MDEFL/!NPENBI>Y%-#Z!LNBYKC+914;U:X%_32;VZ!G#6\!P&3SR>]2M:#7S;
MR[1]T&F3B[F+W#&,YR,XSPSNYQWX49V'LU8S3E4-:&I,O3_\-YV<S;F..>O&
M>6>//JPK&G.+L;_N034)*N*[?R+%1$51:5UMOT0-7Z5?)1QYNU #+38'&0?&
MC\0.'> N/B""01@CJ7]!ERMY0^A_8#4/LW;XL6VY/)>&CA%/S</4[BX?G=BT
M=#=C]F_R,S7T9_:1_,JNVUU1;+A3UM#*Z*JIY!)&]O-K@<A=L[/-54^L=+4E
MUI]ULCAN5$0/\'*/?-]76.XA<.JR=A>M_:EJEM/6R[MHN!$4^3PC=\63P)P>
MX]R8U=/4AE<H7T=_2GA\,Z]1!Q&1R18QMA$4$VR:T;HW24LL#P+I5YAI&]8=
MCB_U-!SZR.U2A%SDHHC.:A%R?@IKRCM;^S%[;IZWRYH+>_,Y:>$D_(CU-XCU
MD]RIE?KWND>Y[W%SW')<3DD]J^Z>&2IJ(H*=CI)I7!C&-&2YQ.  MZNM5Q44
M>>ML=LW)DXV,Z+=K+5L4=0PFUT>)JMW41GT6>MQ'S KLEC6L8UK&AK6C  &
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MG*K>Y9,^&HA&YUQCCQDZB47U1JB6RW:AHXZ%T[:C!+LD$Y.,-[3_ *A2A?A
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M"LM<<;;]5^VG7-4Z"3>H*'-+3X/ AI.\X>MV>/8 F=)5U+._"%=7;TZWCED
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MF8?0)[P>7_O)3"XVJAN49974L4P(QES>(]1YA4SK:R1V*]&G@<702,$L>]S
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M*K)5-L8QQM-+076VJ75:[!0O:U\&H?RIOV7J:+1ZPM<-VM;*>I=(UC90_,9
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AHM'T$5'!',W?E9&UKW#D2!Q**2HEM\O<VUI:4L;4?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
